N/A N=16 Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
Nutritional and Metabolic Diseases
Primary: Number of Test Results Outside the Normal Range — 6; 3; 0; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=81 Novel Therapeutics in Posttraumatic Stress Disorder (PTSD): A Randomized Clinical Trial of Mifepristone
Stress Disorders, Post-Traumatic
Primary: Percentage of Clinical Responders at 4-week Follow-up — 15; 12; 24; 26 Participants
Phase 3 N=289 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer
Cervical Cancer · Endometrial Cancer · Gastrointestinal Complications
Primary: Acute Gastrointestinal Toxicity, as Measured by Change in Expanded Prostate Cancer Index Composite (EPIC) Bowel Domain Score at 5 Weeks From the Start of Pelvic…
N/A N=260 Post-Approval Trial of the Talent™ Abdominal Stent Graft to Treat Aortic Aneurysms
Aortic Aneurysm, Abdominal
Primary: Freedom From Aneurysm-related Mortality (ARM) — .97 Proportion of participants
Phase 4 N=36 Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM
Disorder of Glucose Regulation
Primary: Normalization of Glucose Levels — 9; 2; 4 Participants — p=.035
N/A N=904 Improving High School Breakfast Environments
Obesity
Primary: Change From Baseline in Percent Students Eating the School Breakfast Per School — 8.3; .9 % School Breakfast Participation
Phase 2 N=66 Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD
Chronic Obstructive Pulmonary Disease
Primary: Morning Pre-dose Trough FEV1 — 0.101; 0.098; 0.077; -0.031 Liters
Phase 2 N=37 Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome
Alagille Syndrome
Primary: Change From Baseline to Endpoint (Week 13/Early Termination) in Pruritus — -1.470; -1.486; -0.620; -0.580 Score on a scale — p=0.0321
N/A N=50 Forced-air Warming in Endovascular Surgery: Testing Effectiveness of Two Different Blanket Models
Hypothermia
Primary: Values of Body Temperature ( in Celsius Degree ) in Two Groups of Patients Undergoing EVAR and LEA That Will Use Two Different Types of Bair Hugger 3M Body Warming…
Phase 2 N=32 A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
Acute Myelogenous Leukemia · AML · Acute Myeloid Leukemia
Primary: Objective Remission Rate — 18.8 percentage of participants
Phase 2 N=80 Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension
Chronic Thromboembolic Pulmonary Hypertension
Primary: Change From Baseline to Week 16 in Pulmonary Vascular Resistance (PVR) at Rest. — 73.0; 87.2 percent of baseline PVR — p=0.0410
Phase 3 N=1,498 Cognition in the Study of Tamoxifen and Raloxifene
Cognition · Aging
Primary: Mean Change From Baseline on the the Benton Visual Retention Test Scores by Treatment Group — -0.73; -1.41 Number of errors
Phase 2 N=25 Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants
Phase 2 N=61 Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Ixazomib (Phase 1) — 3; 4; 3; 4 mg
Phase 3 N=107 Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSH-12)
Wounds
Primary: Intra-individual Difference in Time to Wound Closure — -1.4 days — p=<0.0001